Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 714-720

  Ko, Jenny J ^a   Bernard, Brandon ^e   Tran, Ben ^f   Li, Haocheng ^b   Asif, Tehmina ^c   Stukalin, Igor ^b   Lee, Margaret ^f   Day, Daphne ^d   Alimohamed, Nimira ^b   Sweeney, Christopher J ^e   Bedard, Philippe L ^d   Heng, Daniel Y C ^b  

^a Abbotsford Cancer Agency   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c SASKATCHEWAN CANCER AGENCY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; GERM CELL TUMOR; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC TESTICULAR GERM CELL TUMOR; NON SEMINOMATOUS GERMINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SEMINOMA; TERTIARY CARE CENTER; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84964335363     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.7909     Document Type: Article

References (28)

1. Znaor A, Lortet-Tieulent J, Jemal A, et al: International variations and trends in testicular cancer incidence and mortality. Eur Urol 65:1095-1106, 2014
2. Shanmugalingam T, Soultati A, Chowdhury S, et al: Global incidence and outcome of testicular cancer. Clin Epidemiol 5:417-427, 2013
3. Rosen A, Jayram G, Drazer M, et al: Global trends in testicular cancer incidence and mortality. Eur Urol 60:374-379, 2011
4. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
5. International Germ Cell Consensus Classification: Aprognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
6. Merrill RM, Henson DE, Barnes M: Conditional survival among patients with carcinoma of the lung. Chest 116:697-703, 1999
7. Henson DE, Ries LA, Carriaga MT: Conditional survival of 56, 268 patients with breast cancer. Cancer 76:237-242, 1995
8. Kim Y, Ejaz A, Spolverato G, et al: Conditional survival after surgical resection of gastric cancer: A multi-institutional analysis of the US gastric cancer collaborative. Ann Surg Oncol 22:557-564, 2015
9. Harshman LC, Xie W, Bjarnason GA, et al: Conditional survival of patients with metastatic renalcell carcinoma treated with VEGF-targeted therapy: A population-based study. Lancet Oncol 13:927-935, 2012
10. Sun M, Abdollah F, Bianchi M, et al: Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. Eur J Cancer 48:1503-1511, 2012
11. Klein JP, Logan B, Harhoff M, et al: Analyzing survival curves at a fixed point in time. Stat Med 26:4505-4519, 2007
12. Alanee S, Shukla A: Paediatric testicular cancer: an updated review of incidence and conditional survival from the Surveillance, Epidemiology and End Results database. BJU Int 104:1280-1283, 2009
13. Janssen-Heijnen ML, Gondos A, Bray F, et al: Clinical relevance of conditional survival of cancer patients in Europe: Age-specific analyses of 13 cancers. J Clin Oncol 28:2520-2528, 2010
14. Statistics Canada. Conditional survival analyses across cancer sites. http://www.statcan. gc.ca/pub/82-003-x/2011002/article/11425-eng.htm
15. National Comprehensive Cancer Network: Testicular cancer (version 2.2015). http://www.nccn.org/professionals
16. BC Cancer Agency: Clinical management guideline, testicular cancer. http://www.bccancer.bc.ca/health-professionals/professional-resources/cancermanagement-guidelines/genitourinary/testis#Follow-Up
17. van As NJ, Gilbert DC, Money-Kyrle J, et al: Evidence-based pragmatic guidelines for the follow-up of testicular cancer: Optimising the detection of relapse. Br J Cancer 98:1894-1902, 2008
18. Schmoll HJ, Jordan K, Huddart R, et al: Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:89-96, 2009 J Clin Oncol (suppl 4)
19. Princess Margaret Cancer Centre: Princess Margaret Cancer Centre clinical practice guidelines: Genitourinary (testicular cancer). http://www.uhn. ca/PrincessMargaret/Health-Professionals/Programs-Departments/Genitourinary-GU/Documents/CPG-GU-Testis.pdf
20. Alberta Health Services: Testicular germ cell tumour, clinical practice guideline GU-001 version 6. http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu001-testicular.pdf
21. Pan-Birmingham NHS Cancer Network: Guideline for the management of testicular cancer. http://www.uhb.nhs.uk/Downloads/pdf/CancerPbTesticularCancer.pdf
22. Feldman DR, Voss MH, Jacobsen EP, et al: Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer 119:2574-2581, 2013
23. Berney DM, Warren AY, Verma M, et al: Malignant germ cell tumours in the elderly: A histopathological review of 50 cases in men aged 60 years or over. Mod Pathol 21:54-59, 2008
24. Spermon JR, Witjes JA, Kiemeney LA: Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology 60:889-893, 2002
25. Raggi D, Mariani L, Giannatempo P, et al: Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. Urol Oncol 33:332.e19-24, 2015
26. Adra N, Oza A, Albany C, et al: A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 1990 to 2011. J Clin Oncol 32, 2014(suppl; abstr 4557)
27. Ku K, Ibrahim S, Adra N, et al: A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012. J Clin Oncol 33, 2015(suppl; abstr 4539)
28. Albany C, Satpute S, Brames MJ, et al: A retrospective analysis of patients with intermediaterisk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010. J Clin Oncol 30, 2012(suppl; abstr 4534).